Age-related macular degeneration (AMD) is the main cause of low vision and even blindness in the elderly. With the aging of our population, the number of AMD patients will continue to rise. In the past decade, the rapid development of ocular fundus imaging technology has provided a new perspective and approach for the classification, diagnosis and follow-up of AMD. The advent of new drugs has provided more diverse intervention and treatment methods for AMD, especially for neovascular AMD, and the emphasis on accurate and individualized treatment has put forward higher requirements for retinal specialists. Therefore, based on the latest evidence-based medical information, combined with the international guidelines and the current situation of China's social and economic development, experts from the Chinese Vitreo-Retinal Society of Chinese Medical Association, the Fundus Disease Group of Chinese Ophthalmologist Association, and the National Clinical Research Center for Eye Diseases gave recommendations around eight clinical problems and formed China's guidelines for the clinical diagnosis and treatment of AMD. With the implementation of these guidelines, we can standardize the diagnosis, treatment, prevention and follow-up of AMD in China. (This article was published ahead of print on the official website of Chinese Journal of Ophthalmology on April 6, 2023).
年龄相关性黄斑变性(AMD)是老年人群低视力乃至失明的主要原因,随着我国人口老龄化加剧,AMD的患病人数将持续上升。近10年,眼底影像学检查技术飞速发展,为AMD的分型、诊断和随访提供了新的视角和途径,新药的开发为AMD尤其新生血管性AMD提供了更为多样的干预和治疗方法,而强调精准个体化治疗对眼底病医师提出了更高要求。为此,中华医学会眼科学分会眼底病学组、中国医师协会眼科医师分会眼底病学组与国家眼部疾病临床医学研究中心基于最新循证医学证据,结合国际指南和我国社会经济发展现状,围绕8个临床问题提出推荐意见,形成了我国的AMD临床诊疗指南,以期加强和完善我国AMD诊疗工作的规范化,提高我国AMD的诊疗、预防和随访水平。(本文于2023年4月6日优先出版在中华眼科杂志官网).